Overactive Bladder Treatment Market Growth Will Escalate Rapidly 2018-2026 by Global Top Players - Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc., Alembic Pharmaceuticals Ltd., and Pfizer Inc.

Overactive bladder is a common medical condition where there is sudden urge of urination. Overactive bladder is sometimes coupled with urine leakage, condition known as incontinence. Millions of people across the globe suffers from overactive bladder and it is more common in old age people. Urine leakage and frequent urination are the main symptoms of overactive bladder. The frequency of urination in the patient is around eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is commonly diagnosed by tests such as urine culture, bladder scan, cystoscopy or urodynamic testing. Robust drug pipeline with drugs in phase II and phase III clinical trials, soon expected to be in the market, are expected to drive the overactive bladder treatment market growth. However, alternate therapies such as the neuromodulation therapy which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are expected to hinder the overactive bladder treatment market growth.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2007

Overactive Bladder Treatment Market Dynamics -

High prevalence of overactive bladder is expected to propel the overactive bladder treatment market growth over the forecast period. Moreover, increasing awareness about the importance of diagnosis and treatment of the disease is a key factor leading to increase in number of patients treated for overactive bladder.

Increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs such as cholinergic receptor inhibitors are available for treatment of the condition. Therefore, development and approval of new drug entity with better drug profile is expected to boost the market growth.

For instance, in 2018, Urovant Sciences—a biopharmaceutical company that focuses on developing novel therapy for urologic conditions—entered in phase III clinical trial for its drug —Vibegron —an oral Beta-andrenergic agonist for indication of overactive bladder treatment.

Furthermore, Taris Biomedical LLC—entered phase II clinical trials for its drug candidate TAR-302 for the treatment of overactive bladder. TAR 302 is a trospium chloride-based continuous local therapy, which is expected to efficiently aid in treatment of overactive bladder with few side effects.

Overactive Bladder Treatment Market – Competitive Analysis

Key players operating in the overactive bladder treatment market include, Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2007

Overactive Bladder Treatment Market - Taxonomy

On the basis of drug type, the overactive bladder treatment market is segmented into:
Anticholinergics
- Oxybutynin
- Darifenacin
- Fesoterodine
- Solifenacin
- Tolterodine
- Trospium
Mirabegron
Botox

On the basis of route of administration, the overactive bladder treatment market is segmented into:
Topical
Oral
Intravenous

On the basis of distribution channel, the overactive bladder treatment market is segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.